Formulations for the definition of the risk profile at diagnosis
| . | Sokal . | Euro . |
|---|---|---|
| Age (y) | 0.0116 (age, 43.4) | 0.6666 when age 50 or older |
| *Spleen (cm) | 0.0345 (spleen − 7.51) | 0.042 × spleen |
| Platelet (× 109/L) | 1.0956 when 1500 or higher | |
| †Myeloblasts (%) | 0.0887 (myeloblasts − 2.10) | 0.0584 × myeloblasts |
| †Eosinophils (%) | — | 0.0413 × eosinophils |
| †Basophils (%) | — | 0.2039 when basophils at least 3% |
| Relative risk (RR) | Exponential of the total | Total × 1000 |
| . | Sokal . | Euro . |
|---|---|---|
| Age (y) | 0.0116 (age, 43.4) | 0.6666 when age 50 or older |
| *Spleen (cm) | 0.0345 (spleen − 7.51) | 0.042 × spleen |
| Platelet (× 109/L) | 1.0956 when 1500 or higher | |
| †Myeloblasts (%) | 0.0887 (myeloblasts − 2.10) | 0.0584 × myeloblasts |
| †Eosinophils (%) | — | 0.0413 × eosinophils |
| †Basophils (%) | — | 0.2039 when basophils at least 3% |
| Relative risk (RR) | Exponential of the total | Total × 1000 |
In the Sokal30 formulation, all four variables are continuous. In the Euro formulation,28 spleen and myeloblasts are continuous, whereas age and platelet count enter into the calculation only when age is at least 50 years and platelet count is at least 1500 × 109/L. Low-risk patients have an RR less than 0.8 with the Sokal and at most 780 with Euro formulation. Intermediate-risk patients have an RR between 0.8 and 1.2 with the Sokal and between 781 and 1479 with the Euro formulation. High-risk patients have an RR greater than 1.2 with the Sokal and at least 1480 with the Euro method.
Maximum distance from costal margin.
Percent in peripheral blood.